Skip to content
Back to CELC

Celcuity Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
17
Purchases
0
Sales
17
Purchase value
$0.00
Sale value
$327.56M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Baker Bros. Advisors (GP) LLCFormer 10% owner
Baker Bros. Advisors LPFormer 10% owner
Baker FelixFormer 10% owner
Baker JulianFormer 10% owner
4
Filed Jul 16, 2026Period of report Jul 14, 20260001193125-26-306299
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 14, 2026
Common StockF1F2F3261,368$102.50$26.79M442,940IndirectSee Footnotes
SaleJul 14, 2026
Common StockF2F3F42,838,632$102.50$290.96M4,372,852IndirectSee Footnotes
Filing footnotes · 4
  1. F1After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, L.P. ("667"), Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in common stock ("Common Stock") of Celcuity Inc. (the "Issuer") reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
  2. F2Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to 667 and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.
  3. F3Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
  4. F4After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
Open on SEC EDGAR
Richard E BullerDirector
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001688319-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 4, 2026
Common StockF1F21,289$137.00$176.59K14,471IndirectBy Trust
SaleMay 4, 2026
Common StockF1F3F2550$138.9955$76.45K13,921IndirectBy Trust
SaleMay 4, 2026
Common StockF1F4F21,670$139.5832$233.10K12,251IndirectBy Trust
SaleMay 4, 2026
Common StockF1F5F22,301$141.0271$324.50K9,950IndirectBy Trust
SaleMay 4, 2026
Common StockF1F6F22,825$142.0358$401.25K7,125IndirectBy Trust
SaleMay 4, 2026
Common StockF1F7F2365$143.2378$52.28K6,760IndirectBy Trust
Filing footnotes · 8
  1. F1The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2025.
  2. F2The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
  3. F3The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $138.255 to $139.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $139.40 to $140.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $140.50 to $141.33, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  6. F6The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $141.59 to $142.50, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  7. F7The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $143.20 to $143.46, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  8. F8100% vested.
Open on SEC EDGAR
David DalveyDirector
4Rule 10b5-1 plan disclosed
Filed May 6, 2026Period of report May 4, 20260001296457-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 4, 2026
Common StockF1F225,000$140.68$3.52M65,000IndirectBy Brightstone Venture Capital Fund, LP
Filing footnotes · 2
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brightstone Venture Capital Fund, LP ("Brightstone") on August 19, 2025.
  2. F2The reporting person is the General Partner of Brightstone.
Open on SEC EDGAR
Richard E BullerDirector
4Rule 10b5-1 plan disclosed
Filed Apr 2, 2026Period of report Mar 31, 20260001688319-26-000002
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 31, 2026
Common StockF1F3F22,325$110.1057$256.00K7,435IndirectBy Trust
SaleMar 31, 2026
Common StockF1F4F2675$110.8268$74.81K6,760IndirectBy Trust
Filing footnotes · 5
  1. F1The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2025.
  2. F2The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
  3. F3The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $109.505 to $110.48, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  4. F4The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $110.50 to $111.36, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  5. F5100% vested.
Open on SEC EDGAR
David DalveyDirector
4Rule 10b5-1 plan disclosed
Filed Jan 29, 2026Period of report Jan 27, 20260001296457-26-000003
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 27, 2026
Common StockF1F2F320,000$120.0269$2.40M90,000IndirectBy Brightstone Venture Capital Fund, LP
Filing footnotes · 3
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brightstone Venture Capital Fund, LP ("Brightstone") on August 19, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.315, inclusive. The reporting person undertakes to provide Celcuity Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The reporting person is the General Partner of Brightstone.
Open on SEC EDGAR
Richard E BullerDirector
4
Filed Dec 9, 2025Period of report Dec 5, 20250001688319-25-000013
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 5, 2025
Common StockF2F11,490$105.3398$156.96K8,270IndirectBy Trust
SaleDec 5, 2025
Common StockF3F11,510$106.0353$160.11K6,760IndirectBy Trust
Filing footnotes · 4
  1. F1The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
  2. F2The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $105.00 to $105.70, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  3. F3The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $106.00 to $106.45, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  4. F4100% vested.
Open on SEC EDGAR
Richard E BullerDirector
4
Filed Dec 3, 2025Period of report Dec 1, 20250001688319-25-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 1, 2025
Common StockF2F11,100$98.1349$107.95K7,260IndirectBy Trust
Filing footnotes · 3
  1. F1The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
  2. F2The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $98.010 to $98.505, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  3. F3100% vested.
Open on SEC EDGAR
David DalveyDirector
4Rule 10b5-1 plan disclosed
Filed Nov 24, 2025Period of report Nov 21, 20250001296457-25-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 21, 2025
Common StockF1F2F315,000$100.0011$1.50M110,000IndirectBy Brightstone Venture Capital Fund, LP
Filing footnotes · 3
  1. F1These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brightstone Venture Capital Fund, LP ("Brightstone") on August 19, 2025.
  2. F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.03, inclusive. The reporting person undertakes to provide Celcuity Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3The reporting person is the General Partner of Brightstone.
Open on SEC EDGAR
Richard E BullerDirector
4
Filed Nov 21, 2025Period of report Nov 19, 20250001688319-25-000007
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 20, 2025
Common StockF2F13,900$96.732$377.25K7,260IndirectBy Trust
Filing footnotes · 3
  1. F1The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
  2. F2The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $96.465 to $96.920, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
  3. F3100% vested.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.